Ihe ọmụma
Olmesartan medoxomil ntụ ntụ, a na-ewu ewu angiotensin II antagonist, ka edepụtara maka ọgwụgwọ ọbara mgbali elu na nkụda obi. Ọgwụ a na-arụ ọrụ site n'igbochi ọrụ nke angiotensin II, hormone nke na-eme ka arịa ọbara mechie, si otú ahụ na-ebelata ọbara mgbali. Oge kachasị mma maka ịṅụ ọgwụ a-ma n'ụtụtụ ma ọ bụ n'uhuruchi-abụla isiokwu mmasị maka ọtụtụ ndị ọrịa na ndị na-ahụ maka ahụike. Edemede a ga-enyocha ihe ndị na-emetụta oge kacha mma iji were olmesartan medoxomil ntụ ntụ, na-atụle usoro okirikiri nke anụ ahụ, usoro ọbara mgbali elu, na mkpa onye ọrịa ọ bụla.
Mkpa nke oge na nchịkwa ọgwụ enwetawo nlebara anya na-arịwanye elu n'afọ ndị na-adịbeghị anya, dịka ndị nchọpụta na ndị na-ahụ maka ụlọ ọgwụ na-amata mmetụta nke chronotherapy nwere na ịdị irè ọgwụgwọ na nsonaazụ onye ọrịa. Chronotherapy na-ezo aka n'omume ịmekọrịta nchịkwa ọgwụ na usoro usoro ndu nke anụ ahụ iji bulie mmetụta ọgwụgwọ yana belata mmetụta ndị ọzọ. N'ihe banyere ọgwụ antihypertensive dị ka olmesartan medoxomil ntụ ntụ, ịghọta mmekọrịta dị n'etiti oge dose na usoro ọbara mgbali elu nke circadian nke anụ ahụ dị oke mkpa maka inweta njikwa ọbara mgbali kacha mma.
Kedu uru dị n'iji Olmesartan Medoxomil ntụ ntụ na mgbede?
Ahụ mmadụ na-arụ ọrụ na okirikiri nke awa 24 nke a maara dị ka rhythm circadian, nke na-emetụta usoro ahụike dị iche iche, gụnyere ọbara mgbali elu. Ọbara mgbali elu na-agbaso usoro ụbọchị ọ bụla, na-enwe ọkwa dị elu n'ehihie yana imikpu eke n'abalị. Nri abalị a, nke a maara dị ka "ịkụnye," bụ usoro dị mkpa nke anụ ahụ nke na-enye ohere ka usoro obi na-ezu ike ma gbakee.
Nnyocha ụfọdụ na-egosi na ịṅụ ọgwụ ọ̀tụ̀tụ̀ ọbara ji erugharị n'ahụ́ ná mgbede nwere ike ime ka ahụ́ ya kwekọọ n'ọ̀tụ̀tụ̀ ọbara mgbali elu n'abalị. Nkwekọrịta a nwere ike ịkwalite ịdị irè nke ọgwụ ahụ ma nye ọtụtụ uru:
1. Mmezi njikwa ọbara mgbali elu: Ntugharị mgbede nke olmesartan medoxomil ntụ ntụ nwere ike inyere aka ịnọgide na-enwe profaịlụ ọbara mgbali na-agbanwe agbanwe n'ime oge 24-hour. Site n'ịkwalite ntinye nke abalị, ọ nwere ike iduga n'ịchịkwa ọbara mgbali elu ka mma, karịsịa n'oge ụtụtụ ụtụtụ mgbe ọbara mgbali na-amalite ịrị elu.
2. Mbelata ihe ize ndụ nke ihe omume obi: Nnyocha egosiwo na ndị mmadụ na-enweta mgbatị nkịtị nke abalị na ọbara mgbali elu nwere obere ihe ize ndụ nke ihe omume obi ma e jiri ya tụnyere ndị na-adịghị etinye aka. Site n'ịkwalite itinye nri n'ime mgbede, olmesartan medoxomil ntụ ntụ nwere ike itinye aka na mbelata ihe egwu obi.
3. Nchedo megide ịwa ahụ nke ụtụtụ: A na-ejikọta awa ụtụtụ n'isi na mmụba ebumpụta ụwa nke ọbara mgbali elu, nke na-adaba n'ihe ize ndụ dị ukwuu nke ọrịa obi dị ka nkụchi obi na ọrịa strok. Nri mgbede nke olmesartan medoxomil ntụ ntụ nwere ike inye aka belata ịwa ahụ nke ụtụtụ a site n'ịhụ na mmetụta ọgwụ ahụ dị n'ogo kachasị elu n'oge oge a dị oke egwu.
4. Nchekwa akụkụ ahụ nke Pụrụ Iche: Nnyocha ụfọdụ na-egosi na ị theụ ọgwụ mgbochi ọbara n'uhuruchi nwere ike inye nchebe ka mma maka akụkụ ahụ ndị na-enwe mmetụta karịsịa maka mgbanwe ọbara mgbali, dị ka akụrụ na obi.
5. Ọdịmma ụra dị mma: Ọ bụ ezie na ọ bụghị ihe jikọrọ ya na njikwa ọbara mgbali elu, ụfọdụ ndị ọrịa na-akọ na ụra dị mma mgbe ha na-ewere olmesartan medoxomil ntụ ntụ na mgbede. Nke a nwere ike ịbụ n'ihi mmetụta kachasị nke ọgwụ na-eme n'oge awa ụra, nwere ike ibelata mgbanwe ọbara mgbali elu nke abalị.
Nlekọta ụtụtụ nke Olmesartan Medoxomil ntụ ntụ nwere ike inye uru ọ bụla?
Ọ bụ ezie na a na-atụkarị aro ka ị na-aṅụ ọgwụ mgbali elu n'uhuruchi, enwere ike ịnwe ọnọdụ ebe nchịkwa ụtụtụ nke olmesartan medoxomil ntụ ntụ dabara adaba. Uru ụfọdụ nwere ike ịdị n'iji ọgwụ ụtụtụ eme ihe gụnyere:
1. Nkwenye ka mma: Ọtụtụ ndị ọrịa na-adị mfe icheta ịṅụ ọgwụ ha n'ụtụtụ dị ka akụkụ nke usoro ha na-eme kwa ụbọchị. Nke a na-eme ka ọ dịkwuo mma nwere ike ime ka njikwa ọbara mgbali elu dịkwuo mma, ebe ọ bụ na ịchịkọta ọnụ na ịṅụ ọgwụ dị oké mkpa maka ịchịkwa ọbara mgbali elu.
2. Njikwa Nrụgide Ọbara n'ehihie: Maka ndị ọrịa ọbara mgbali elu na-adị elu n'ụbọchị, dose nke ụtụtụ nwere ike inye njikwa dị mma n'oge elekere anya mgbe ha na-arụsi ọrụ ike ma nwee ike kpughee mbelata ọbara mgbali elu metụtara nrụgide.
3. Mbelata oge mmamịrị abalị: Ụfọdụ ndị ọrịa na-enweta mmụba mmamịrị dị ka mmetụta dị n'akụkụ nke olmesartan medoxomil ntụ ntụ. Ịṅụ ọgwụ ahụ n'ụtụtụ nwere ike inye aka belata njem ịsa ahụ nke abalị, nwere ike ime ka ụra dịkwuo mma.
4. Nlekọta nke Orthostatic Hypotension: Maka ndị ọrịa na-enwekarị hypotension orthostatic (mbelata ọbara mgbali elu na mberede na-eguzo ọtọ), dose nke ụtụtụ nwere ike ịka mma iji zere ime ka ọnọdụ a dịkwuo njọ n'oge nleta ụlọ ịsa ahụ n'abalị.
5. Nkwekọrịta na ọgwụ ndị ọzọ: Ọ bụrụ na onye ọrịa na-aṅụ ọtụtụ ọgwụ, nchịkọta ụtụtụ nke olmesartan medoxomil ntụ ntụ nwere ike ịdị mfe karị ma nyere aka mee ka usoro ọgwụgwọ ha dị mfe.
Kedu ka oge Olmesartan Medoxomil Powder si emetụta njikwa ọbara mgbali?
Oge ọgwụgwọ nwere ike imetụta ịdị irè ya nke ukwuu, ọkachasị maka ọnọdụ dị ka ọbara mgbali elu ebe ọbara mgbali elu na-adịgasị iche kwa ụbọchị. Iji ghọta mmetụta nke oge dosing na njikwa ọbara mgbali elu, ọ dị mkpa ịtụle pharmacokinetics na pharmacodynamics nke olmesartan medoxomil ntụ ntụ:
Pharmacokinetics: Olmesartan medoxomil bụ ọgwụ na-agbanwe ngwa ngwa na kpamkpam na olmesartan, metabolite ya na-arụ ọrụ, n'oge nnabata site na eriri afọ. A na-erute mkpokọta plasma kacha elu (Cmax) nke olmesartan n'ihe dịka awa 1-2 mgbe nchịkwa ọnụ gasịrị, na nkwụsị ọkara ndụ ya bụ awa 10-15. Ogologo ndụ ọkara a dị ogologo na-enye ohere ị theụ ọgwụ otu ugboro kwa ụbọchị.
Pharmacodynamics: Olmesartan na-arụ ọrụ antihypertensive ya site na ịhọrọ nke ọma igbochi njikọ nke angiotensin II na onye na-anabata AT1 na akwara dị nro. Ihe mgbochi a na-eduga na vasodilation na mbelata ọbara mgbali. Mmalite nke mmetụta antihypertensive dị ngwa ngwa, na-eme n'ime izu 1-2 nke ịmalite ọgwụgwọ, yana mmetụta zuru oke na-ahụkarị n'ime izu asatọ.
Mgbe ị na-atụle oge nchịkwa olmesartan medoxomil ntụ ntụ, ọ dị mkpa ijikọta akụrụngwa ọgwụ ndị a na usoro ọbara mgbali elu nke circadian:
1. Ọgwụ mgbede: Ịta olmesartan medoxomil ntụ ntụ na mgbede pụtara na mmetụta ya kachasị elu nwere ike ime n'isi ụtụtụ mgbe ọbara mgbali na-amalite ịrị elu. Oge a nwere ike inye aka gbochie mmụba ọbara nke ụtụtụ ma nọgide na-achịkwa nke ọma n'ụbọchị dum.
2. Nri ụtụtụ: Ịnye ọgwụ n'ụtụtụ na-ebute ọkwa ọbara kacha elu n'ụbọchị mgbe ọbara mgbali na-adịkarị elu n'ihi mmega ahụ na nchekasị. Oge a nwere ike inye njikwa ọbara mgbali elu ka mma nke ụbọchị mana ọ nwere ike ghara ịdị irè n'ịhazi ịwa ahụ n'isi ụtụtụ.
3. Profaịlụ mgbali ọbara nke awa 24: Ogologo ndụ ọkara nke olmesartan na-enye ohere maka njikwa ọbara mgbali elu n'ime oge awa 24, n'agbanyeghị oge dose. Agbanyeghị, oge nsonaazụ kacha elu nwere ike imetụta profaịlụ ọbara mgbali elu yana ogo ntinye nke abalị.
4. Ngbanwe nke onye: Ọ dị mkpa iburu n'obi na nzaghachi olmesartan medoxomil ntụ ntụ nwere ike ịdịgasị iche n'etiti ndị mmadụ n'otu n'otu n'ihi ihe ndị dị ka mkpụrụ ndụ ihe nketa, afọ, ọrịa nje na ọgwụ na-ejikọta ọnụ. Mgbanwe a na-egosi mkpa ọ dị maka ụzọ ahaziri onwe ya maka oge dose.
5. Chronopharmacology: Usoro nke ime ime ahụ nwere ike imetụta mmịnye ọgwụ, nkesa, metabolism, na nsị. Mmetụta oge nke oge a nwere ike imetụta oge kachasị mma nke nchịkwa ntụ ntụ olmesartan medoxomil, ọ bụ ezie na ọ dị mkpa nyocha ọzọ iji kọwaa mmekọrịta ndị a n'ụzọ zuru ezu.
mmechi
Na-ekpebi oge kacha mma iji were olmesartan medoxomil ntụ ntụ na-achọ ụzọ ahaziri onwe ya, n'ịtụle usoro ụda okirikiri nke onye ọrịa, usoro ọbara mgbali elu, na ụzọ ndụ ya. Ọ bụ ezie na ịdoụ ọgwụ mgbede nwere ike inye ụfọdụ uru, dị ka ntinye aka nke abalị na njikwa mma nke ọbara mgbali elu nke ụtụtụ, nchịkwa ụtụtụ nwere ike ịka mma maka ụfọdụ ndị mmadụ, karịsịa ndị na-agbasi mbọ ike na-agbaso ọgwụ ma ọ bụ na-enwe mmetụta ndị na-egbochi ụra.
Ekwesịrị ịme mkpebi maka mgbe ị ga-ewere ntụ ntụ olmesartan medoxomil na ndị na-ahụ maka ahụike, dabere na ihe akaebe kacha mma dị na ọnọdụ pụrụ iche nke onye ọrịa. Ihe ndị a ga-atụle gụnyere:
1. Ụdị ọbara mgbali elu nke ọ bụla, dị ka ekpebisiri ike na nlele ọbara mgbali elu elekere 24
2. Ọnụnọ nke ọrịa na-efe efe, dị ka ọrịa shuga ma ọ bụ ọrịa akụrụ, nke nwere ike imetụta mkpa nchịkwa ọbara mgbali
3. Mmasị ndị ọrịa na ihe ndị na-ebi ndụ nwere ike imetụta nnabata ọgwụ
4. Mmekọrịta enwere ike na ọgwụ ndị ọzọ na usoro onye ọrịa
5. ndidi na profaịlụ mmetụta
Ọ dị mkpa iburu n'uche na n'agbanyeghị oge nchịkwa a họọrọ, nkwụsi ike bụ isi n'ijikwa ntụ ntụ olmesartan medoxomil. Ekwesịrị ịgba ndị ọrịa ume ka ha na-aṅụ ọgwụ ha n'otu oge kwa ụbọchị na ịkọrọ ndị na-ahụ maka ahụike ha nchegbu ma ọ bụ mmetụta ọ bụla.
Ka nyocha na chronotherapy na-aga n'ihu na-etolite, nghọta anyị maka oge kachasị mma maka ọgwụ antihypertensive dị ka olmesartan medoxomil ntụ ntụ nwere ike nụchaa. Ọmụmụ ihe n'ọdịnihu nwere ike ịnye ntụzịaka doro anya na usoro ọgwụgwọ ahaziri iche nke na-ebuli uru ọgwụgwọ ma na-ebelata mmetụta ndị nwere ike ime.
Ka ọ dị ugbu a, ndị na-ahụ maka ahụike kwesịrị ịdị na-emeghe maka ịhazigharị oge nke olmesartan medoxomil ntụ ntụ nchịkwa dabere na nzaghachi onye ọrịa n'otu n'otu na mmasị. Nleba anya nke ọbara mgbali elu mgbe niile, ma n'ụlọ ọgwụ ma n'ụlọ, nwere ike inye aka na-eduzi mkpebi ndị a ma hụ na ndị ọrịa na-enweta ma nọgide na-achịkwa ọbara mgbali elu kacha mma.
Ọ bụrụ na ị nwekwara mmasị na ngwaahịa a ma chọọ ịmatakwu nkọwa ngwaahịa, ma ọ bụ chọọ ịmata maka ngwaahịa ndị ọzọ metụtara, biko nweere onwe gị ịkpọtụrụ. iceyqiang@gmail.com.
References:
1. "Circadian Rhythms na oge nke ọgwụ mgbali ọbara." Akwụkwọ akụkọ ọbara mgbali elu, vol. 36, mba. 4, 2018, p. 829-836 .
2. "N'uhuruchi vs. Morning Dosing of Antihypertensive Medicines: Mmetụta na nsonaazụ Cardiovascular." Mgbasa: Ogo obi na nsonaazụ, vol. 11, mba. 3, 2018, peeji e004121.
3. "Pharmacokinetics nke Olmesartan Medoxomil na ihe ọ pụtara maka oge nchịkwa." Clinical Pharmacology & Therapeutics, vol. 105, mba. 1, 2019, p. 193-199 .
4. "Ụkpụrụ ntinye nke ọbara mgbali elu na njikọ ya na oge ọgwụgwọ." Akwụkwọ akụkọ American Journal of Hypertension, vol. 32, mba. 2, 2019, peeji 185-192 .
5. "Ụtụtụ vs. Nri abalị nke ọgwụ mgbochi hypertensive: Nyochaa nhazi usoro." Akwụkwọ akụkọ nke Clinical Pharmacy and Therapeutics, vol. 44, mba. 3, 2019, p. 444-453 .
6. "Mmetụta nke mgbede vs. Morning Olmesartan Medoxomil Dosage on Ambulatory Blood Pressure." Ọbara mgbali elu, vol. 72, mba. 4, 2018, p. 851-858 .
7. "Ọgwụ nkeonwe na ọgwụgwọ ọbara mgbali elu: Ọrụ nke oge ọgwụ." Akwụkwọ akụkọ European of Internal Medicine, vol. 58, 2019, peeji 1-6.
8. "Ịrapagidesi ike na ọgwụ mgbochi hypertensive na mmetụta nke oge dose." Mmasị ndị ọrịa na nrube isi, vol. 13, 2019, p. 1677-1684.
9. "Mmetụta nke oge ọgwụgwọ na mgbanwe ọbara mgbali." Akwụkwọ akụkọ ọbara mgbali elu nke mmadụ, vol. 34, mba. 2, 2020, p. 123-129 .
10. "Olmesartan Medoxomil: Nlebanya nke ojiji ya na njikwa ọbara mgbali elu." Ahụike Vascular na njikwa ihe egwu, vol. 15, 2019, peeji 155-165 .
Ihe ọmụma ụlọ ọrụ emetụtara
